Every 8-K that Cardio Diagnostics Holdings Inc (CDIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CDIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIO filings page.
Cardio Diagnostics Holdings, Inc. (CDIO) reported that senior management is using a new August 2026 investor presentation to brief existing and prospective investors. The company focuses on AI- and epigenetics-based blood tests for cardiovascular disease risk stratification (Epi+Gen CHD) and diagnosis (PrecisionCHD), supported by a proprietary multi-omics engine and a growing IP portfolio across multiple jurisdictions.
The presentation highlights large estimated U.S. market opportunities for these tests, a company-owned CLIA lab intended to lower costs and increase capacity, and progress toward reimbursement, including specific CPT PLA codes, a final CMS payment rate, and initial commercial coverage. It also outlines ongoing and planned clinical, economic, and utility studies, as well as U.S. and international commercialization efforts. The investor materials are furnished under Regulation FD and are not deemed filed or incorporated by reference into Securities Act filings.
Cardio Diagnostics Holdings is hosting an investor call to review its current status, recent developments, and strategic priorities, supported by an investor presentation. The company focuses on precision cardiovascular medicine using epigenetics and artificial intelligence to prevent and detect heart disease earlier and more accurately.
The presentation highlights two AI-powered blood tests: Epi+Gen CHD, which estimates three-year coronary heart disease risk and has an estimated U.S. market of about $125 billion with 146 million eligible Americans, and PrecisionCHD, a diagnostic aid with an estimated $51 billion U.S. market and 60 million eligible Americans, both tied to a final CMS payment rate of $854 per test. Management emphasizes growing clinical validation, cost-effectiveness studies, and international partnerships, including a recently launched internal CLIA lab that has reduced initial lab cost of goods by roughly 30% and targets test turnaround times of about 7–10 business days.
Cardio Diagnostics Holdings, Inc. reported results from its annual meeting held on October 15, 2025 under Item 5.07. A quorum was present with 927,526 shares voting out of 1,763,129 outstanding as of the record date, approximately 52.6%. Stockholders elected seven directors to one-year terms by plurality.
Stockholders approved the Share Issuance Proposal authorizing future issuances of common stock and/or convertible or exercisable securities equal to 20% or more of outstanding common stock in one or more non‑public transactions, within the parameters described in the proxy statement. Votes were 283,304 for, 166,492 against, and 15,183 abstaining, with 462,547 broker non‑votes.
They also ratified Prager Metis CPA’s LLC as independent auditor for the year ending December 31, 2025, with 813,401 for, 64,820 against, and 49,305 abstentions.